Pancreatic Cancer Research

ResearcherFox Chase Cancer CenterNo recent work listed

Michael J. Hall

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4515-3409; OpenAlex author ID A5009072858. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper

Papers 12

  1. Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Co-author DOI 10.1177/17588359231189127↗
  2. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  3. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Co-author DOI 10.1158/1078-0432.ccr-22-0275↗
  4. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  5. Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? First author DOI 10.5306/wjco.v12.i2.54↗
  6. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/esmoopen-2020-000942↗
  7. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the… Last author DOI 10.1200/jco.19.01890↗
  8. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1903387↗
  9. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000619↗
  10. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advan… Co-author DOI 10.1016/j.radonc.2014.08.014↗
  11. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Co-author DOI 10.1007/s10637-010-9526-z↗
  12. Significance of pathologic response to preoperative therapy in pancreatic cancer. Co-author DOI 10.1245/s10434-011-2086-4↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Talia Golan · 4 shared papers, 2019–2023 · strength 0.49
  2. Pascal R. Hammel · 4 shared papers, 2019–2023 · strength 0.49
  3. Anthony Frank Shields · 4 shared papers, 2014–2022 · strength 0.35
  4. Hedy Lee Kindler · 4 shared papers, 2012–2022 · strength 0.32
  5. Wolfgang Michael Korn · 3 shared papers, 2020–2022 · strength 0.31
  6. John Lindsay Marshall · 3 shared papers, 2020–2022 · strength 0.31
  7. Daniel Hochhauser · 3 shared papers, 2019–2022 · strength 0.29
  8. Dirk Arnold · 3 shared papers, 2019–2022 · strength 0.29
  9. Michele Reni · 3 shared papers, 2019–2022 · strength 0.29
  10. Eric Van Cutsem · 3 shared papers, 2019–2022 · strength 0.29
  11. Teresa Mercade Macarulla · 3 shared papers, 2019–2022 · strength 0.29
  12. Philip A. Philip · 3 shared papers, 2014–2022 · strength 0.24
  13. Joshua E. Meyer · 2 shared papers, 2014–2021 · strength 0.23
  14. Emil Lou · 2 shared papers, 2022 · strength 0.23
  15. Joon Oh Park · 2 shared papers, 2020–2022 · strength 0.22
  16. Raffaella Casolino · 1 shared paper, 2023 · strength 0.20
  17. Douglas L. Riegert‐Johnson · 1 shared paper, 2023 · strength 0.20
  18. Wafik S. El‐Deiry · 2 shared papers, 2020–2022 · strength 0.20
  19. Andrew Victor Biankin · 1 shared paper, 2023 · strength 0.20
  20. Eileen Mary O'Reilly · 2 shared papers, 2019–2022 · strength 0.20
  21. Do‐Youn Oh · 2 shared papers, 2019–2022 · strength 0.20
  22. Giampaolo Tortora · 2 shared papers, 2019–2022 · strength 0.20
  23. Anke Reinacher‐Schick · 2 shared papers, 2019–2022 · strength 0.20
  24. Hana Algül · 2 shared papers, 2019–2022 · strength 0.20
  25. Andreas Seeber · 2 shared papers, 2020–2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.